Qi Liping MD, Presenter: Nothing to Disclose

Xiao-peng Zhang MD, Abstract Co-Author: Nothing to Disclose

Kun Cao MD, Abstract Co-Author: Nothing to Disclose

Ying-shi Sun MD, Abstract Co-Author: Nothing to Disclose

Lei Tang MD, Abstract Co-Author: Nothing to Disclose

To evaluate if diffusion-weighted MR imaging (DWI) can early detect and predict response for combination chemotherapy of non-small cell carcinoma (NSCLC).

Thirty-six consecutive patients enrolled in this study. Most patients received two cycles of combination chemotherapy. DWI, T2-weighted and T1-weighted imaging were schemed to be acquired at four time points, which were baseline, early time point, after the first cycle and after the second cycle. DWI was acquired by single shot echo planar imaging (SS-EPI) sequence with b=0，500s/mm2. Based on viable tumor volume reduction rate(VRR) measured on T2W images, responses were identified as responders (VRR≥65%) and non-responders(VRR＜65%).ADC increase, volume and the longest diameter(LD) reduction rate were compared between two groups. Receiver operation curves (ROC) were used to analyze accuracy of diagnosis.

Of thirty-six cases 31 patients attended early time point and 23 cases (10 responders, 13 non-responders) could obtain ADCs at baseline and early time point. The ADC increase in responders was significant and much larger than that in non-responders, 31%±18% and 1%±11% respectively. ADC increase at early time point was correlated with final VRR. At early time point, the volume and LD decrease in responders was significantly larger than that in non-responders. Area under curve was 0.962(p<0.001), 0.785(p=0.035), 0.677（p=0.154）for ADC increase, volume decrease and LD decrease respectively. The ROC of ADC increase was superior to that of volume decrease for predicting response. But LD decrease was of no value to predicting response. The difference of volume and LD decrease between two groups was smallest at early time point, but was the most significant for ADC increase.

DWI at the end of chemotherapeutic agent administration in the first cycle may help early detect chemotherapy response and be a superior tool to size change to predict treatment effect of NSCLC patients.

DWI at the end of chemotherapeutic agent administration in the first cycle may help early detect chemotherapy response and predict treatment effect of NSCLC patients .

Liping, Q, Zhang, X, Cao, K, Sun, Y, Tang, L, DWI for Detecting Early ADC Increasing and Predicting Chemotherapy Effect of NSCLC.  Radiological Society of North America 2008 Scientific Assembly and Annual Meeting, February 18 - February 20, 2008 ,Chicago IL. http://archive.rsna.org/2008/6019661.html